For patients with an advanced-stage tumor, the predicted expression of MKI67 overlapped neatly with the tumor area, while for more early stages we observed less discriminate patterns: AUCaverage = 0.63 (AUCmedian = 0.65) for patients with BCLC stage A, AUCaverage = 0.63 (AUCmedian = 0.62) for patients with BCLC stage B, and AUCaverage = 0.74 (AUCmedian = 0.76) for patients with BCLC stage C (Table 3). This evidence concerns the gene MKI67 and neoplasm.